Search results
Showing 976 to 990 of 1047 results for drug therapy
Evidence-based recommendations on Sleepio to treat insomnia and insomnia symptoms.
Evidence-based recommendations on KardiaMobile for detecting atrial fibrillation.
Avapritinib for treating advanced systemic mastocytosis (TA1012)
Evidence-based recommendations on avapritinib (Ayvakyt) for treating advanced systemic mastocytosis in adults.
Evidence-based recommendations on tocilizumab (RoActemra) for treating giant cell arteritis in adults.
Evidence-based recommendations on imlifidase (Idefirix) for desensitisation treatment before kidney transplant in people with chronic kidney disease.
NICE has developed a medtech innovation briefing (MIB) on digital technologies for the detection of melanoma .
Evidence-based recommendations on selumetinib (Koselugo) for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over.
Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disorders (TA748)
Evidence-based recommendations on mexiletine (Namuscla) for treating the symptoms of myotonia in adults with non-dystrophic myotonic disorders.
Faecal microbiota transplant for recurrent Clostridioides difficile infection (HTG638)
Evidence-based recommendations on faecal microbiota transplant for recurrent Clostridioides difficile infection.
Evidence-based recommendations on SonoVue (sulphur hexafluoride microbubbles) for contrast-enhanced ultrasound imaging of the liver.
Evidence-based recommendations on exagamglogene autotemcel (Casgevy) for treating severe sickle cell disease in people 12 years and over.
Evidence-based recommendations on viscoelastometric point-of-care testing devices (the ROTEM, TEG and Sonoclot systems).
Tarlatamab for extensive-stage small-cell lung cancer after 2 or more treatments (TA1091)
Evidence-based recommendations on tarlatamab (IMDYLLTRA) for treating extensive-stage small-cell lung cancer after 2 or more treatments in adults.
Show all sections
Evidence-based recommendations on osimertinib (Tagrisso) for adjuvant treatment of stage 1b to 3a non-small-cell lung cancer after complete tumour resection in adults.
Show all sections
Evidence-based recommendations on procalcitonin testing for diagnosing and monitoring sepsis (ADVIA Centaur BRAHMS PCT assay, BRAHMS PCT Sensitive Kryptor assay, Elecsys BRAHMS PCT assay, LIAISON BRAHMS PCT assay and VIDAS BRAHMS PCT assay).